Dogwood Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 3,384,798 shares, representing 9.99% of Dogwood Therapeutics, Inc.'s common stock.
NASDAQ
Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 3,343,120 shares, representing 9.99% of Dogwood Therapeutics, Inc.'s common stock.
NASDAQ
SCHEDULE 13G/A: Orca Capital AG Discloses 3.7% Stake in Dogwood Therapeutics Following Recent Offering
Orca Capital AG has filed an amended Schedule 13G, reporting a 3.7% beneficial ownership stake in Dogwood Therapeutics, Inc. as of March 14, 2025, following the issuer's recent registered offering.
NASDAQ
Orca Capital AG, a German entity, has reported a 6.1% beneficial ownership stake in Dogwood Therapeutics, Inc., following the issuer's recent registered offering.